Abstract 1420P
Background
FGFR2b protein is emerging as a potential therapeutic target in patients with advanced GC/GEJC. This study investigated the estimated prevalence of FGFR2b protein overexpression and its overlap with actionable biomarkers.
Methods
Tumor samples from 130 Japanese patients diagnosed with advanced/metastatic GC/GEJC between 01 January 2021 and 31 October 2022 were analyzed. FFPE samples collected before 1L were tested via immunohistochemistry (IHC) for FGFR2b [clone FPR2-D] and PD-L1 [clone 28-8]. HER2, MMR and Claudin 18 [clone 43-14A] expression were also assessed. FGFR2b overexpression was defined as any percentage of tumor cells exhibiting moderate (2+) to strong (3+) membranous staining (FGFR2b any 2+/3+). FGFR2b overexpression of ≥10% of tumor cells exhibiting 2+ to 3+ membranous staining (FGFR2b ≥10% 2+/3+) was also evaluated.
Results
Estimated prevalence of FGFR2b any 2+/3+ was 29% (95% CI: 22, 39) and of FGFR2b ≥10% 2+/3+ was 11% (95% CI: 6, 17). In HER2 negative FGFR2b any 2+/3+ tumor samples, 16% exhibited a PD-L1 CPS ≥ 5 and 36% expressed Claudin 18 in ≥75% of tumor cells at 2+ or 3+ staining. For HER2 negative FGFR2b ≥10% 2+/3+ tumor samples, those proportions were 14% and 43%, respectively. Select biomarker overlap is summarized in the table. Table: 1420P
Overlap of HER2, PD-L1, MMR, Claudin 18, and FGFR2b in advanced or metastatic G/GEJ cancer tumor samples from a Japanese cohort
| Within HER2 Negative | ||||||
| Total | HER2 positive | HER2 negative | PD-L1 CPS ConclusionsThis real-world study estimated the prevalence of FGFR2b protein overexpression in GC/GEJC, revealing limited overlap with currently actionable biomarkers such as PD-L1 and Claudin 18 in tumor samples from a Japanese cohort. Clinical trial identificationEditorial acknowledgementLegal entity responsible for the studyAmgen Inc. FundingAmgen Inc. DisclosureS.L. Rhodes, E. Finger, C. Chang, R.E. Yanes, H. Honeycutt: Financial Interests, Personal, Full or part-time Employment: Amgen; Financial Interests, Personal, Stocks or ownership: Amgen. Y. Aoki: Financial Interests, Personal, Invited Speaker: Guardant Health Inc. I. Nakayama: Financial Interests, Institutional, Local PI: Chugai Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, MSD. Y. Nakamura: Financial Interests, Personal, Invited Speaker: Chugai, Merck Biopharma, Guardant Health Pte Ltd., MSD K.K, Eisai, Zeria Pharmaceutical, Miyarisan Pharmaceutical, CareNet, Inc., Hisamitsu Pharmaceutical, Taiho Pharmaceutical, Daiichi Sankyo Co., Ltd., Becton Dickinson, Guardant Health Japan Corp.; Financial Interests, Personal, Advisory Board: Natera, Inc., Roche Ltd., Seagen, Inc., Premo Partners, Inc., Daiichi Sankyo Co., Ltd., Takeda, Exact Sciences, Gilead Sciences, Guardant Health Pte Ltd; Financial Interests, Institutional, Funding: Taiho, Chugai, Guardant Health, Genomedia, Daiichi Sankyo, Roche Diagnostics, Guardant Health AMEA, Inc., Tempus; Financial Interests, Institutional, Coordinating PI: Seagen. A. Kawazoe: Financial Interests, Personal, Advisory Board: Zymeworks, Merck & Co.; Financial Interests, Personal, Invited Speaker: Taiho Pharmaceutical Co., Ltd., Daiichi Sankyo Company, Limited, Eli Lilly, Bristol Myers Squibb, Ono Pharmaceutical Co., Ltd. D. Kotani: Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Chugai, Daiichi Sankyo, Eli Lilly, MSD, Merck Biopharma, Ono pharma, Pfizer, Taiho pharma, Takeda, Sysmex, Nihonkayaku, Novartis, Guardant Health; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Institutional, Local PI: Ono pharma, MSD, Servier, Novartis, Janssen pharma, IQVIA, Syneos Health, CIMIC Shiftzero, CIMIC; Financial Interests, Institutional, Funding: Ono pharma. Y. Kuboki: Financial Interests, Personal, Advisory Board: Takeda, Amgen, Abbie, Incyte, Boehringer Ingelheim; Financial Interests, Personal, Invited Speaker: Taiho, Lilly; Financial Interests, Institutional, Local PI: Taiho, Astellas, Lilly, Takeda, AstraZeneca, Boehringer Ingelheim, Chugai, Genmab, Incyte, Abbie, Merck, Novartis, Hengrui; Financial Interests, Institutional, Coordinating PI: Amgen; Non-Financial Interests, Member: JSMO, ASCO, JSCO, JCA. H. Bando: Financial Interests, Institutional, Research Grant: Ono Pharmaceutical; Other, Lecture fee: Ono Pharmaceutical, Taiho Pharmaceutical, Eli Lilly Japan. T. Kojima: Financial Interests, Personal, Invited Speaker: MSD, Bristol Myers Squibb, Ono Pharmaceutical; Financial Interests, Personal, Advisory Board: Boehringer Ingelheim, Kyowa Kirin, Taiho Pharmaceutical; Financial Interests, Institutional, Local PI: AstraZeneca, BeiGene, MSD, Amgen, Chugai Pharmaceutical, Taiho Pharmaceutical, Shionogi Pharma, Amgen Astellas BioPharma. T. Yoshino: Financial Interests, Personal, Invited Speaker: Chugai Pharmaceutical Co., Ltd., Merck Biopharma Co., Ltd., Bayer Yakuhin, Ltd., Ono Pharmaceutical Co., Ltd., MSD K.K., Takeda Pharmaceutical Co., Ltd.; Financial Interests, Personal, Other, Consultancy: Sumitomo Corp.; Financial Interests, Institutional, Research Grant: Ono Pharmaceutical Co., Ltd., Sanofi K.K., MSD K.K., Taiho Pharmaceutical Co., Ltd., Molecular Health GmbH, Amgen K.K., Pfizer Japan Inc., Genomedia Inc., Sysmex Corp., Daiichi Sankyo Co., Ltd., Chugai Pharmaceutical Co., Ltd., Nippon Boehringer Ingelheim Co., Ltd., Eisai Co., Ltd., Roche Diagnostics K.K., FALCO Biosystems Ltd., Merus N.V., Bristol Myers Squibb K.K., Medical & Biological Laboratories Co., LTD., Takeda Pharmaceutical Co., Ltd. K. Shitara: Financial Interests, Personal, Advisory Board: Bristol Myers Squibb, Takeda, Ono Pharmaceutical, MSD, Novartis, Daiichi Sankyo, Amgen, Guardant Health Japan Corp, Astellas Pharma Inc., Astellas, Bayer, AstraZeneca, Zymeworks Biopharmaceuticals Inc., ALX Oncology Inc.; Financial Interests, Personal, Invited Speaker: Bristol Myers Squibb, Janssen, AstraZeneca, Eli Lilly, Astellas, Ono Pharmaceutical; Financial Interests, Institutional, Research Grant: Astellas, Ono Pharmaceutical, Daiichi Sankyo, Taiho Pharmaceutical, Chugai Pharmaceutical, MSD, Eisai, Amgen, PRA Health Sciences. All other authors have declared no conflicts of interest. Resources from the same session961P - Sodium-glucose co-transporter 2 inhibitors (SGLT2i) improve oncologic outcomes in diabetic patients with hepatocellular carcinoma (HCC): A nationwide database studyPresenter: Chien-Huai Chuang Session: Poster session 17 962P - Best practices and impact of multi-disciplinary teams on hepatocellular carcinoma treatment: Insights from a global effortPresenter: Pablo Azcue Session: Poster session 17 963P - Quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis to assess the impact of treatment with camrelizumab + rivoceranib (cam+rivo) on quality of life vs sorafenib (sora) in patients (pts) with unresectable hepatocellular carcinoma (uHCC): Study CARES-310Presenter: Andrew Moon Session: Poster session 17 964P - Lenvatinib (L) and sorafenib (S) in patients (pts) with advanced or unresectable hepatocellular carcinoma (uHCC): An international, multicenter, phase IV study (STELLAR)Presenter: Markus Peck Radosavljevic Session: Poster session 17 967P - Lenvatinib (L) versus sorafenib (S) second-line therapy in hepatocellular carcinoma (HCC) patients (P) progressed to atezolizumab plus bevacizumab (AB)Presenter: Mara Persano Session: Poster session 17 968P - HAIC combined with lenvatinib and PD-1 inhibitors versus lenvatinib plus PD-1 inhibitors for advanced HCC with portal vein tumor thrombosis: A prospective controlled trialPresenter: Xiaodong Wang Session: Poster session 17 969P - Lenvatinib versus sorafenib as a second-line option in patients with unresectable hepatocellular carcinoma previously treated with atezolizumab plus bevacizumab: An observational studyPresenter: Pasquale Lombardi Session: Poster session 17 970P - Comparing clinical outcomes between PD-1 and PD-L1 inhibitors plus bevacizumab combined with hepatic arterial interventional therapies in unresectable hepatocellular carcinoma: A single-center, real-world studyPresenter: Yangxun Pan Session: Poster session 17 Resources: Abstract 971P - Chemotherapy combined with lenvatinib and PD-1 may be a potential better alternative optionfor advanced unresectable intrahepatic cholangiocarcinoma: A retrospective real-world studyPresenter: binghua dai Session: Poster session 17 This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used. For more detailed information on the cookies we use, please check our Privacy Policy.
| |||